Research programme: monoclonal antibody therapeutics - Aduro BioTech

Drug Profile

Research programme: monoclonal antibody therapeutics - Aduro BioTech

Alternative Names: BION-1301

Latest Information Update: 09 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aduro BioTech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD27 antigen inhibitors; CD70 antigen inhibitors; Cytotoxic T-lymphocyte antigen 4 modulators; PDCD 1 protein inhibitors; Tumour necrosis factor ligand superfamily member 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple myeloma
  • Research Cancer

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Multiple myeloma presented at the 108th Annual Meeting of the American Association of Cancer Research (AACR-2017)
  • 01 Mar 2017 Aduro Biotech announces intention to file IND for BION 1301 to the US FDA in the second half of 2017
  • 03 Dec 2016 Preclinical trials in Multiple myeloma in USA (Parenteral) before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top